

SUBSTITUTE DISCLOSURE FORM (PTO-1449) (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
				FILING DATE January 7, 2004		GROUP Unknown	


U.S. PATENT DOCUMENTS									
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
ME	A.A	5 8 7 1 7 2 3	02/16/99	Strieter et al.	424	85.1	06/06/1995		
	A.B								
	A.C								
	A.D								
	A.E								
	A.F								
	A.G								
	A.H								
	A.I								
	A.J								
	A.K								

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
ME	A.L	WO0162274	08/03/2001	PCT - Spain	A61K 38/19	Abstract only	
ME	A.M	WO9421277	09/29/2004	PCT - US	A61K 37/02	N/A	
ME	A.N	WO9404670	03/03/1994	PCT - US	C12N 15/00	N/A	
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
ME	A.R	PCT, <u>International Search Report</u> , PCT/US2004/O00199, dated August 10, 2004, 6 pages
ME	A.S	Kaplan AP, <u>Chemokines, Chemokine Receptors and Allergy</u> , International Archives of Allergy and Immunology 124(4):423-431 (2001), XP009034299
ME	A.T	Medoff B et al., <u>IFN-γ-Inducible Protein 10 (CXCL10) Contributes to Airway Hyperreactivity and Airway Inflammation in a Mouse Model of Asthma</u> , The Journal of Immunology 168(10):5278-5287 (2002), XP002289900

EXAMINER <div style="text-align: center; font-size: 1.5em;">ME</div>	DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">1/17/06</div>
---	---

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;">  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use several sheets if necessary)</p> </div> <div style="margin-left: 20px;"> <p>APPLICANT Mark Elliot Rothenberg et al.</p> </div> </div>				FILING DATE January 7, 2004			
				GROUP Unknown			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
<i>PL</i>	B.R	Sgadari C et al., <u>Mig, the Monokine Induced by Interferon-γ, Promotes Tumor Necrosis in Vivo</u> , Blood 89 (8):2635-2643 (1997)					
<i>PL</i>	B.S	Thomas MS et al., <u>Role of IP-10 in a Cockroach Antigen Induced Muring Model of Airway Hyperreactivity</u> , FASEB Journal 16(4):A331 (2002) XP009034300, Abstract 245.3					
	B.T						
EXAMINER <i>PL</i>				DATE CONSIDERED 1/27/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED) <div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; display: flex; align-items: center; justify-content: center; margin: 10px auto;"> <div style="text-align: center;"> MAY 10 2004 (37) </div> </div>		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	A.A						
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
A.L							
A.M							
A.N							
A.O							
A.P							
A.Q							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
<i>ML</i>	A.R	Combadiere et al., <u>Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor</u> , J. Bio. Chem. 270:16491-16494 (1995) and 271:11034 (1996)
↓	A.S	Daugherty et al., <u>Cloning, Expression, and Characterization of the Human Eosinophil Eotaxin Receptor</u> , J. Exp. Med. 183:2349-2354 (1996)
<i>ML</i>	A.T	Forssmann et al., <u>Eotaxin-2, a Novel CC Chemokine that is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes</u> , J. Exp. Med. 185:2171-2176 (1997)





EXAMINER <div style="text-align: center; font-size: 1.5em;"><i>ML</i></div>	DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">1/17/06</div>
--	---

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
B.L							
B.M							
B.N							
B.O							
B.P							
B.Q							





OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	B.R	Gerber et al., <u>Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils</u> , Curr. Biol. 7:836-843 (1997)
	B.S	Heath et al., <u>Chemokine Receptor Usage by Human Eosinophils</u> , J. Clin. Invest. 99:178-184 (1997)
	B.T	Jinquan et al., <u>CXCR3 Expression and Activation of Eosinophils: Role of IFN-g-Inducible Protein-10 and Monokine Induced by IFN-g</u> , J. Immunol. 165:1548-56 (2000)
EXAMINER 		DATE CONSIDERED 1/17/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	C.A						
	C.B						
	C.C						
	C.D						
	C.E						
	C.F						
	C.G						
	C.H						
	C.I						
	C.J						
	C.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
C.L							
C.M							
C.N							
C.O							
C.P							
C.Q							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	C.R	Kitaura et al., <u>Molecular Cloning of a Novel Human CC Chemokine (Eotaxin-3) That Is a Functional Ligand of CC Chemokine Receptor 3</u> , J. Biol. Chem. 274:27975-80 (1999)
	C.S	Loetscher et al., <u>The Ligands of CXCR Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3</u> , J. Biol. Chem. 276:2986-91 (2001)
	C.T	Lukacs, <u>Role of Chemokines in the Pathogenesis of Asthma</u> , Natue Rev. Immunol. 1:108-16 (2001)
EXAMINER 		DATE CONSIDERED 1/17/06

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	D.R	Luster, <u>Chemokines - Chemotactic Cytokines That Mediate Inflammation</u> , N. Eng. J. Med. 338:436-445 (1998)
	D.S	Mathews et al., <u>Eotaxin is required for the baseline level of tissue eosinophils</u> , Proc. Natl. Acad. Sci. U.S.A. 95:6273-78 (1998)
	D.T	Mishra et al., <u>An etiological role for aeroallergens and eosinophils in experimental esophagitis</u> , J. Clin. Invest. 107:83-90 (2001)

EXAMINER 	DATE CONSIDERED 1/17/06
------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A						
	E.B						
	E.C						
	E.D						
	E.E						
	E.F						
	E.G						
	E.H						
	E.I						
	E.J						
	E.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L						
	E.M						
	E.N						
	E.O						
	E.P						
	E.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
M	E.R	Nickel et al., <u>Chemokines and allergic disease</u> , J. Allergy Clin. Immunol. 104:723-742 (1999)					
I	E.S	Patel et al., <u>Molecular and Functional Characterization of Two Novel Human C-C Chemokines as Inhibitors of Two Distinct Classes of Myeloid Progenitors</u> , J. Exp. Med. 185:1163-1172 (1997)					
M	E.T	Ponath et al., <u>Molecular Cloning and Characterization of a Human Eotaxin Receptor Expressed Selectively on Eosinophils</u> , J. Exp. Med. 183:2437-2448 (1996)					
EXAMINER				DATE CONSIDERED			
RAE				1/17/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161	SERIAL NO. 10/752,659		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
PRL	F.R	Pope et al., <u>IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism</u> , J. Allergy Clin. Immunol. 108:594-601 (2001)					
↓	F.S	Power et al., <u>The chemokine system: novel broad-spectrum therapeutic targets</u> , Curr. Opin. Pharmacol. 1:417-24 (2001)					
PRL	F.T	Rollins, <u>Chemokines</u> , Blood 90:909-928 (1997)					
EXAMINER PRL				DATE CONSIDERED 11/17/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	G.R	Rothenberg et al., <u>Murine eotaxin: An eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression</u> , Proc. Natl. Acad. Sci. 92:8960-8964 (1995)
	G.S	Rothenberg et al., <u>Eotaxin Triggers Eosinophil-Selective Chemotaxis and Calcium Flux via a Distinct Receptor and Induces Pulmonary Eosinophilia in the Presence of Interleukin 5 in Mice</u> , Molecular Medicine 2:334-348 (1996)
	G.T	Rothenberg, <u>Eotaxin: An Essential Mediator of Eosinophil Trafficking into Mucosal Tissues</u> , Am. J. Respir. Cell Mol. Biol. 21:291-295 (1999)

EXAMINER 	DATE CONSIDERED 1/17/06
------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(Use several sheets if necessary)							
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
RA	H.R	Rothenberg, <u>Eosinophilia</u> , N. Eng. J. Med. 338:1592-1600 (1998)					
↓	H.S	Rothenberg, <u>Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia</u> , J. Exp. Med. 185:785-790 (1997)					
↓ RA	H.T	Sallusto et al., <u>Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells</u> , Science 277:2005-2007 (1997)					
EXAMINER				DATE CONSIDERED			
RA				1/17/06			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
I.L							
I.M							
I.N							
I.O							
I.P							
I.Q							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
<i>RL</i>	I.R	Shinkai et al., <u>A Novel Human CC Chemokine, Eotaxin-3, Which Is Expressed in IL-4-Stimulated Vascular Endothelial Cells, Exhibits Potent Activity Toward Eosinophils</u> , J. Immunol. 163:1602-1610 (1999)
<i>I</i>	I.S	Stellato et al., <u>Characterization of CCR3 Expression on Human Airway Epithelial Cells</u> , J. Allergy Clin. Immunol. 103 (No. 1 Pt. 2): S194 (1999)
<i>HL</i>	I.T	Uguccioni et al., <u>High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils Role in Activation by Eotaxin, MCP-4, and Other Chemokines</u> , J. Clin. Invest. 100:1137-1143 (1997)




EXAMINER <div style="text-align: center; font-size: 1.5em;"> <i>RL</i> </div>	DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;"> <i>1/17/06</i> </div>
--	--


EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
	J.R	Youn et al., <u>Molecular Cloning of Leukotactin-1: A Novel Human beta-Chemokine, a Chemoattractant for Neutrophils, Monocytes, and Lymphocytes, and a Potent Agonist at CC Chemokine Receptors 1 and 3</u> , J. Immunol. 159:5201-5205 (1997)
	J.S	Zhang et al., <u>Differential Effects of Leukotactin-1 and Macrophage Inflammatory Protein-1alpha on Neutrophils Mediated by CCR1</u> , J. Immunol. 162:4938-4942 (1999)
	J.T	Zhu et al., <u>Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production</u> , J. Clin. Invest. 103:779-788 (1999)

EXAMINER 	DATE CONSIDERED 1/17/06
---	--------------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. CMC/161		SERIAL NO. 10/752,659	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT Mark Elliot Rothenberg et al.			
(37 CFR 1.98(b))				FILING DATE January 7, 2004		GROUP Unknown	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A.						
	K.B.						
	K.C.						
	K.D.						
	K.E.						
	K.F.						
	K.G.						
	K.H.						
	K.I.						
	K.J.						
	K.K.						
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L.						
	K.M.						
	K.N.						
	K.O.						
	K.P.						
	K.Q.						
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)							
M	K.R.	Zimmermann et al., <u>CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization</u> , J. Biol. Chem. 274:12611-12618 (1999)					
/	K.S.	Zimmermann et al., <u>Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and IL-4 Overexpression</u> , J. Immunol. 165:5839-5846 (2000)					
✓ M	K.T.	Zimmermann et al., <u>Molecular Analysis of CCR-3 Events in Eosinophilic Cells</u> , J. Immunol. 164:1055-1064 (2000)					
EXAMINER <div style="text-align: center; font-size: 1.5em;">PSE</div>				DATE CONSIDERED <div style="text-align: center; font-size: 1.5em;">1/17/06</div>			
EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance <u>and</u> not considered. Include a copy of this form with next communication to applicant.							